Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="1"><hr/></td></tr><tr><td class="align_left">Main</td></tr><tr><td class="align_left"> Male patients</td></tr><tr><td class="align_left"> ECOG: 0</td></tr><tr><td class="align_left"> Extrahepatic metastases</td></tr><tr><td class="align_left"> HBV infection</td></tr><tr><td class="align_left" colspan="2"><hr/></td></tr><tr><td class="align_left">Independent</td></tr><tr><td class="align_left"> Age</td></tr><tr><td class="align_left"> Alpha-fetoprotein</td></tr><tr><td class="align_left"> Macrovascular invasion</td></tr><tr class="table-tr"><td colspan="1"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Eligibility criteria for overall survival benefit with ramucirumab, cabozantinib, and regorafenib as the second line of treatment for HCC.</div>

Journal of Oncology

tab3

Table 3

Table 3: Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 